IN8bio Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share N/A
Dividend & YieldN/A$ (N/A)
Beta N/A
Market capitalization 36.51M
Operating cash flow -18.35M
ESG Scores unknown

Company description

IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities -152k 141k -160k -319k
Total Cashflows From Investing Activities -757k 356k -309k -309k
Net Borrowings 1.26M 174k 174k -709k
Total Cash From Financing Activities 8.5M 65k 24.52M 32.95M
Change To Operating Activities -703k -78k 771k -1.52M
Issuance Of Stock 65k 65k 512k 36.36M
Net Income -2.08M -5.13M -8.56M -14.65M
Change In Cash 4.97M -4.38M 17.38M 19.14M
Effect Of Exchange Rate
Total Cash From Operating Activities -2.77M -4.8M -7.13M -13.51M
Depreciation 96k 96k 88k 788k
Change To Account Receivables -30k 30k
Other Cashflows From Financing Activities -1.43M -1.43M -1.43M -2.69M
Change To Netincome 97k 144k 725k 2.19M
Capital Expenditures -757k -330k -309k -309k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 581k 2.36M 5.38M 7.35M
Income Before Tax -2.08M -5.13M -8.56M -14.65M
Net Income -2.08M -5.13M -8.56M -14.65M
Selling General Administrative 1.42M 2.71M 3.18M 7.31M
Gross Profit
Ebit -2M -5.07M -8.56M -14.65M
Operating Income -2M -5.07M -8.56M -14.65M
Interest Expense -14k
Income Tax Expense
Total Revenue
Cost Of Revenue
Total Other Income ExpenseNet -77k -68k
Net Income From Continuing Ops -2.08M -5.13M -8.56M -14.65M
Net Income Applicable To Common Shares -2.51M -5.91M -10.34M -14.65M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 419k 647k 2.59M 4.04M
Total Stockholder Equity -4.25M -9.24M -16.58M 38.18M
Other Current Liabilities 876k
Total Assets 5.89M 1.13M 20.91M 42.22M
Common Stock 1k 1k 1k 2k
Other Current Assets 37k
Retained Earnings -4.35M -9.48M -18.04M -32.69M
Treasury Stock
Cash 4.99M 610k 17.99M 37.02M
Total Current Liabilities 419k 647k 2.57M 2.26M
Other Stockholder Equity
Property, Plant, and Equipment 795k 274k 186k 2.83M
Total Current Assets 5.07M 763k 18.14M 38.98M
Net Tangible Assets -4.25M -9.24M -16.58M 38.18M
Net Receivables 30k
Accounts Payable 419k 560k 620k 395k


Insider Transactions

Here are the insider transactions of stock shares related to IN8bio Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
KREIS LESLIE W JRPurchase at price 2.02 per share.I2022-09-28Director and Beneficial Owner of more than 10% of a Class of Security25k
KREIS LESLIE W JRPurchase at price 2.01 - 2.02 per share.I2022-08-29Director and Beneficial Owner of more than 10% of a Class of Security51.21k
FLETCHER AARON G.L.Purchase at price 1.93 per share.I2022-08-17Director and Beneficial Owner of more than 10% of a Class of Security50k
KREIS LESLIE W JRPurchase at price 1.93 per share.I2022-08-17Director and Beneficial Owner of more than 10% of a Class of Security50k
FAIRBAIRN EMILY WANGPurchase at price 1.90 per share.I2022-08-16Director and Beneficial Owner of more than 10% of a Class of Security789.47k
BRANDT PETER CPurchase at price 1.90 per share.D2022-08-16Director105.26k
ROEMER ALAN S.Purchase at price 1.90 per share.D2022-08-16Director26.32k
FLETCHER AARON G.L.Purchase at price 1.90 per share.I2022-08-16Director and Beneficial Owner of more than 10% of a Class of Security1.77M
HO WILLIAM TAI WEIPurchase at price 1.90 per share.D2022-08-16Chief Executive Officer26.32k
GREENWOOD LUBAPurchase at price 1.90 per share.D2022-08-16Director526
LAMB LAWRENCE S.Purchase at price 1.90 per share.D2022-08-16Officer526
MCCALL PATRICK CPAPurchase at price 1.90 per share.D2022-08-16Chief Financial Officer5.26k
GOSWAMI TRISHNAPurchase at price 1.90 per share.D2022-08-16Officer2.63k
ROCHLIN KATE PH.D.Purchase at price 1.90 per share.D2022-08-16Chief Operating Officer5.26k
LAMB LAWRENCE S.Conversion of Exercise of derivative security at price 1.07 per share.D2022-05-05Officer26.2k
FAIRBAIRN EMILY WANGPurchase at price 10.00 per share.I2021-08-03Director and Beneficial Owner of more than 10% of a Class of Security100k
FAIRBAIRN EMILY WANGI2021-08-03Director and Beneficial Owner of more than 10% of a Class of Security3.33M
FLETCHER AARON G.L.I2021-08-03Beneficial Owner of more than 10% of a Class of Security6.63M
KREIS LESLIE W JRI2021-08-03Beneficial Owner of more than 10% of a Class of Security6.63M
HO WILLIAM TAI WEII2021-08-03Chief Executive Officer3.07k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to IN8bio Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on IN8bio Inc

Here is the result of two systematic investment strategies applied to IN8bio Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on IN8bio Inc

The following chart shows the equity curve of the two systematic investment strategies applied to IN8bio Inc:

IN8bio Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 0% on the backtest period.

Performance at glance

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

0.0 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on IN8bio Inc

This is the result of two momentum investment strategies applied to IN8bio Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on IN8bio Inc

The following chart shows all the entries opened by the momentum investment system on IN8bio Inc:

IN8bio Inc momentum entries
  • The first momentum investment strategy would give 26.58% of return on IN8bio Inc. That represents 67.26$ of latent gain with 253.08$ of employed capital.
  • The second momentum investment strategy would give 0% of return on IN8bio Inc. That represents 0.0$ of latent gain with 0.0$ of employed capital.
Performance at glance (1Q Momentum)

Performance

26.58 %

Latent gain

67.26 $

Invested capital

253.08 $

Annualized return

-0.0 %
Performance at glance (2Q Momentum)

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

-0.0 %

Momentum equity curve on IN8bio Inc

The following chart shows the equity curve of the two momentum strategies applied to IN8bio Inc:

IN8bio Inc momentum equity

Note: the dividends potentially given by IN8bio Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on IN8bio Inc

The following chart shows the employed capital evolution of the two momentum strategies on IN8bio Inc since the beginning:

IN8bio Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on IN8bio Inc

Buy the dip entry openings on IN8bio Inc

IN8bio Inc

The performance achieved by the robo-advisor on IN8bio Inc is 0%. That represents 0.0$ of latent gain with 0.0$ of employed capital. The following chart shows IN8bio Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of IN8bio Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

-0.0 %

Equity curve of the strategy applied to IN8bio Inc

The following chart shows the result of the investment strategy applied to IN8bio Inc:

IN8bio Inc

Note: the dividends potentially given by IN8bio Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on IN8bio Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on IN8bio Inc:

IN8bio Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on IN8bio Inc

In this section, I will compare the three previous investment strategies applied to IN8bio Inc.

Equity curve comparison on IN8bio Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

IN8bio Inc investment strategy comparison

Employed capital comparison on IN8bio Inc

IN8bio Inc investment comparison

Performance comparison on IN8bio Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 0% 0.0$ 0.0$ 0.0%
Momentum 1 quarter 26.58% 67.26$ 253.08$ 443.0%
Momentum 2 quarters 0% 0.0$ 0.0$ -0.0%
Non-directional 0% 0.0$ 0.0$ -0.0%
Annualized return comparison

Automatic investment

0.0 %

Momentum 1Q

-0.0 %

Momentum 2Q

-0.0 %

Non-directional

-0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with IN8bio Inc:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between IN8bio Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of IN8bio Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name IN8bio Inc
Country United States
City New York
Address 350 5th Avenue
Phone 646 600 6438
Website in8bio.com
FullTime employees 26
Industry Biotechnology
Sector Healthcare
Exchange XNAS
Ticker INAB
Market www.nasdaq.com

IN8bio Inc ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown